- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
AI-Powered Liver Tumor Ablation Software Leverages CT, MRI and Ultrasound for Real-Time Image Guidance
Through the use of artificial intelligence (AI) and imaging modalities such as ultrasound, CT, and MRI, the newly FDA-cleared VisAble.IO software reportedly enhances planning and real-time assessment for liver tumor ablation procedures.
The Food and Drug Administration (FDA) has granted 510(k) clearance for VisAble.IO (TechsoMed), an artificial intelligence (AI)-enabled software that may facilitate improved real-time imaging guidance — through ultrasound and computed tomography (CT) or magnetic resonance imaging (MRI) — for liver tumor ablation procedures.
TechsoMed said the software’s advanced computation and image registration elevate the planning and real-time assessment of liver tumor ablation.
The company noted that key benefits of the VisAble.IO software include:
• three-dimensional (3D) anatomical views of ablation targets;
• overlay positioning of virtual instruments and ablation region estimates onto imaging; and
• immediate post-procedure 3D views to assess ablation margins and potentially missed volumes.
“There is a real need for a good and efficient assessment tool, and (VisAble.IO) can serve any physician performing thermal ablations,” noted Ryosuke Tateishi, M.D., Ph.D., an associate professor in the Department of Gastroenterology at the University of Tokyo.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
